Abstract:Background Patients with relapsed or refractory (R/R) lymphomas have benefited from chimeric antigen receptor (CAR)-T-cell therapy. However, this treatment is linked to a high frequency of adverse events (AEs), such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematologic toxicity. There has been increasing interest in hematological toxicity in recent years, as it can result in additional complications, such as infection or hemorrhage, which remain intractable. Methods We conducted a retrospective, single-institution study to evaluate the patterns and outcomes of cytopenia following CAR-T-cell infusion and potential associated factors. Results Overall, 133 patients with R/R lymphoma who received CAR-T-cell therapy from June, 2017 to April, 2022 were included in this analysis. Severe neutropenia, anemia and thrombocytopenia occurred frequently (71, 30 and 41%, respectively) after CAR-T-cell infusion. A total of 98% of severe neutropenia and all severe thrombocytopenia cases occurred in the early phase. Early severe cytopenia was associated with CRS incidence and severity, as well as peak inflammatory factor (IL-6, C-reactive protein (CRP), and ferritin) levels. In multivariate analysis, prior hematopoietic stem cell transplantation (HSCT), baseline hemoglobin (HB), and lymphodepleting chemotherapy were independent adverse factors associated with early severe cytopenia. In addition, 18% and 35% of patients had late neutrophil- and platelet (PLT)-related toxicity, respectively. In multivariate analysis, lower baseline PLT count was an independent factor associated with late thrombocytopenia. More severe cytopenia was associated with higher infection rates and poorer survival. Conclusions This research indicates that improved selection of patients and management of CRS may help to decrease the severity of cytopenias and associated AEs and improve survival following CAR-T-cell therapy. Clinical Trial Registration https://www.clinicaltrials.gov/ct2/show/NCT03196830 , identifier NCT03196830.

Hematologic Cytopenia Post CAR T Cell Therapy: Etiology, Potential Mechanisms and Perspective.

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Symptoms of Hematologic Tumors Patients after CAR-T Therapy: a Systematic Review and Meta-Analysis

Coagulation Disorders after Chimeric Antigen Receptor T Cell Therapy: Analysis of 100 Patients with Relapsed and Refractory Hematologic Malignancies

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Mechanisms and management of CAR T toxicity

Optimization Strategies in CAR T-cell Therapy: A Comprehensive Evaluation of Cytopenia, HLH/MAS, and Other Adverse Events

Prolonged haematologic toxicity in CAR-T-cell therapy: A review

Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T‐cells (CAR‐T): A comprehensive review on incidence, risk factors and current management

The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions

Toxicities and related improvements of CAR-T Cell in the treatment of cancer

Toxicity and management in CAR T-cell therapy

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Current Progress in CAR-T Cell Therapy for Hematological Malignancies

Application of CAR-T Cell Immunotherapy in the Treatment of Hematological Malignancy

Inflammatory abrasion of hematopoietic stem cells: a candidate clue for the post-CAR-T hematotoxicity?

Chimeric antigen receptor-T cell therapy for T cell-derived hematological malignancies

Coagulation abnormalities associated with CAR‐T‐cell therapy in haematological malignancies: A review

Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy